Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.
San Diego, California, London, UK, and Houston, Texas, July 24, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson ...
Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma commences on track NY-ESO-1 TCR/IL-15 NK is the lead clinical program of Syena, a Replay and MD Anderson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results